相关实验视频

Updated: Jan 18, 2026

Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane

Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane

Published on: March 16, 2015

是CABP2相关的听力损失 (DFNB93) 是基因治疗的目标吗? 临床前进展和患者登记

Barbara Vona^1,2,3,4, Bernd Wollnik^1,4,5, Nicola Strenzke^2,4,6

¹Institute of Human Genetics University Medical Center Göttingen Göttingen Germany.

|September 10, 2025

概括

与CABP2基因变异相关的遗传性听力损失 (DFNB93) 可以通过基因疗法治疗. 临床前研究表明,通过准内毛细胞突触功能,可以恢复听力.

科学领域:

神经科学是一个神经科学.
遗传学是一个遗传学.
耳鼻喉科耳鼻喉科耳鼻喉科

背景情况:

CABP2基因中的双变异通过影响内毛细胞 (IHC) 突触功能,导致非综合征性听力损失 (DFNB93).
DFNB93被归类为听觉突触病,这是由受损的IHC突触引起的听力障碍.

研究的目的:

审查遗传性听力损失的临床前基因替代研究.
突出CABP2作为病毒介导基因疗法恢复听力的有希望的候选基因.
概述治疗开发的理想遗传标的特征.

主要方法:

对人类CABP2研究和临床前治疗开发的当前文献的综述.
对DFNB93小鼠模型的分析,以了解CaBP2在突触声音编码中的作用.
检查受影响家庭的耳声学排放,以评估外皮毛细胞的功能.

主要成果:

在DFNB93小鼠模型中缺乏CaBP2,由于CaV1.3 Ca2+通道的增强失活,导致突触声音编码受损.
临床前研究表明,基因治疗DFNB93.3的可行性.
有证据表明,CABP2基因疗法是可行的策略,用于恢复听力听力突触.

结论:

CABP2基因疗法具有治疗DFNB93遗传性听力损失的巨大潜力.
听觉突触是听力恢复的有希望的治疗点,正如OTOF基因试验所支持的那样.
引入了一份患者登记册,以促进研究参与,并向CABP2基因治疗临床试验迈进.

关键词:

这是DFNB93 驾驶室2 座2 座结合蛋白2是一种结合蛋白.听力损伤听力损伤患者登记册患者登记册突触病 (synaptopathy) 是一种突触病.

更多相关视频

Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse

Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse

Published on: March 2, 2018

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Published on: October 11, 2024

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...